Is It Time To Reassess IDEXX Laboratories (IDXX) After Its Strong 1 Year Share Price Run?

Simply Wall St.03-28

If you are wondering whether IDEXX Laboratories at around US$573 per share still makes sense for your portfolio, the key question is what you are actually paying for the underlying business. The stock...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622779198?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/29729-main-header/1756252961457","is_english":true,"pubTime":"2026-03-28 03:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622779198","market":"nz","top_or_hot":-1,"title":"Is It Time To Reassess IDEXX Laboratories (IDXX) After Its Strong 1 Year Share Price Run?","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether IDEXX Laboratories at around US$573 per share still makes sense for your portfolio, the key question is what you are actually paying for the underlying business. The stock...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-idxx/idexx-laboratories/news/is-it-time-to-reassess-idexx-laboratories-idxx-after-its-str\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time To Reassess IDEXX Laboratories (IDXX) After Its Strong 1 Year Share Price Run?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time To Reassess IDEXX Laboratories (IDXX) After Its Strong 1 Year Share Price Run?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-28 03:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-idxx/idexx-laboratories/news/is-it-time-to-reassess-idexx-laboratories-idxx-after-its-str><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether IDEXX Laboratories at around US$573 per share still makes sense for your portfolio, the key question is what you are actually paying for the underlying business. The stock...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-idxx/idexx-laboratories/news/is-it-time-to-reassess-idexx-laboratories-idxx-after-its-str\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GB00B4LPDJ14.GBP","symbol_name":"FUNDSMITH EQUITY \"R\" (GBP) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-idxx/idexx-laboratories/news/is-it-time-to-reassess-idexx-laboratories-idxx-after-its-str","article_id":"2622779198","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/29729-main-header/1756252961457"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-idxx/idexx-laboratories/news/is-it-time-to-reassess-idexx-laboratories-idxx-after-its-str","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622779198","pubTimestamp":1774638741,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether IDEXX Laboratories at around US$573 per share still makes sense for your portfolio, the key question is what you are actually paying for the underlying business.\nThe stock has delivered a 35.7% return over the last year, even as the share price shows a 1.1% decline over 7 days, an 11.7% decline over 30 days, and a 14.4% decline year to date. These shifts can change how investors think about both upside and risk.\nRecent coverage has focused on IDEXX Laboratories...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"GB00B4LPDJ14.GBP":"FUNDSMITH EQUITY \"R\" (GBP) ACC","LU2404859741.USD":"FUNDSMITH EQUITY FUND \"R\" (USD) INC","LU0345774391.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) ACC","LU2404859667.USD":"FUNDSMITH EQUITY FUND \"R\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0690374961.EUR":"FUNDSMITH EQUITY \"R\" (EUR) INC","BK4082":"医疗保健设备","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","LU0690374615.EUR":"FUNDSMITH EQUITY \"R\" (EUR) ACC","BK4504":"桥水持仓","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","BK4588":"碎股","IDXX":"爱德士实验室","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","GB00B4QBRK32.GBP":"FUNDSMITH EQUITY \"R\" (GBP) INC","BK4567":"ESG概念","BK4585":"ETF&股票定投概念"},"translate_title":"IDEXX Laboratories(IDXX)股价连续一年强劲上涨后，是时候重新评估它了吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDXX":1.5,"DCF":1},"content_text":"If you are wondering whether IDEXX Laboratories at around US$573 per share still makes sense for your portfolio, the key question is what you are actually paying for the underlying business. The stock has delivered a 35.7% return over the last year, even as the share price shows a 1.1% decline over 7 days, an 11.7% decline over 30 days, and a 14.4% decline year to date. These shifts can change how investors think about both upside and risk. Recent coverage has focused on IDEXX Laboratories as a major player in veterinary diagnostics and animal health services, with attention on how pet care spending and diagnostic adoption trends influence expectations for the company. This context helps explain why the share price can be sensitive to changing views on long term demand, even without company specific announcements hitting the headlines. Against that backdrop, IDEXX Laboratories currently scores 1/6 on Simply Wall St's valuation checks, giving it a value score of 1 out of 6. The next sections will walk through standard valuation methods investors often use and then finish with a different way to think about what this price really implies.  IDEXX Laboratories scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown. AdvertisementApproach 1: IDEXX Laboratories Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model estimates what a company might be worth today by projecting its future cash flows and then discounting those back to a single present value figure. For IDEXX Laboratories, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow stands at about $1.03b. Analyst inputs and extrapolated estimates suggest free cash flow of $1.90b in 2030, with annual figures between 2026 and 2035 ranging from $1.11b to $2.58b in the projection set, all in $. When those projected cash flows are discounted back, the DCF model points to an estimated intrinsic value of about $522.28 per share. Compared with the current share price of around $573, this implies the stock is roughly 9.8% overvalued based on these cash flow assumptions. Result: ABOUT RIGHT IDEXX Laboratories is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act. IDXX Discounted Cash Flow as at Mar 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for IDEXX Laboratories. Approach 2: IDEXX Laboratories Price vs Earnings For a profitable company, the P/E ratio is a straightforward way to link what you pay per share to the earnings the business is already generating. It helps you see how many dollars of price you are paying for each dollar of current earnings. What counts as a “normal” P/E depends on how the market views a company’s growth potential and risk. Higher expected growth and lower perceived risk usually justify a higher P/E, while slower growth and higher risk tend to point to a lower, more cautious multiple. IDEXX Laboratories currently trades on a P/E of 43.09x. That sits above the Medical Equipment industry average P/E of 27.73x and above the peer average of 26.97x, so the market is currently paying a higher multiple for IDEXX earnings than for many peers. Simply Wall St’s Fair Ratio is a proprietary estimate of what P/E might make sense for IDEXX given its earnings growth profile, industry, profit margins, market cap and risk. Because it adjusts for these company specific factors, it can be more informative than a simple comparison with peers or the broad industry. For IDEXX, the Fair Ratio is 29.61x, which is below the current P/E of 43.09x, suggesting the shares trade above this framework’s indication of fair value. Result: OVERVALUED NasdaqGS:IDXX P/E Ratio as at Mar 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies. Upgrade Your Decision Making: Choose your IDEXX Laboratories Narrative Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach a clear story about IDEXX Laboratories to the hard numbers by linking your view of its revenue, earnings and margins to a financial forecast, turning that into a Fair Value, and then comparing that Fair Value with today’s price. This is all done within an easy tool on the Community page that updates automatically when new earnings, guidance or news arrives. For IDEXX you might see one investor building a Narrative around a higher Fair Value such as US$823 based on stronger recurring diagnostics and software assumptions, while another focuses on a lower Fair Value such as US$579 with more cautious growth and margin inputs. You can use those different Narratives side by side to decide whether the current price near US$573 looks high, low or about in line with the story you believe. Do you think there's more to the story for IDEXX Laboratories? Head over to our Community to see what others are saying! NasdaqGS:IDXX 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622779198","isCrawlerRequest":true}